Baricitinib Therapy in COVID-19

Sponsor
Fabrizio Cantini
Study ID
NCT04358614
Phase
PHASE2/PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Retrospective study on the efficacy of baricitinib in 12 COVID-19 patients with moderate pneumonia.

Key Dates

Start date
Mar 16, 2020
Status verified
Apr 2020
Primary completion
Apr 5, 2020
Completion
Apr 7, 2020

Study Design

Enrollment
12 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Active Comparator: Case patients
    Consecutive patients with COVID moderate pneumonia treated with baricitinib tablets 4 mg/day
  • Other: Controls
    Consecutive patients with COVID moderate pneumonia treated with standard therapy before the date of the first baricitinib-treated patient.

Primary Outcome Measure

To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate. [ Time Frame: 2 weeks ]

Related Studies